Showing results (51-60 of 142) with videos related to

Sort By:
Pageof 15
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 22, 2015
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trialStefan H Hohnloser, Riccardo Cappato, Michael D Ezekowitz, et al.
The American Journal of Medicine|June 6, 2016
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial FibrillationGiulia Renda, Marco Zimarino, Fabrizio Ricci, et al.
American Heart Journal|September 7, 2016
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Paul Sanders, et al.
The Lancet. Neurology|November 10, 2010
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialHans-Christoph Diener, Stuart J Connolly, Michael D Ezekowitz, et al.
Circulation|September 25, 2003
Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factorEmmanuelle Jeanpierre, Thierry Le Tourneau, Isabelle Six, et al.
Circulation. Arrhythmia and Electrophysiology|October 22, 2009
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS studyTaya V Glotzer, Emile G Daoud, D George Wyse, et al.
Heart (British Cardiac Society)|May 6, 2014
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
Stroke|January 2, 2010
Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic eventsPaul D Ziegler, Taya V Glotzer, Emile G Daoud, et al.
American Heart Journal|August 2, 2017
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|January 28, 2020
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT TrialPaulus Kirchhof, Michael D Ezekowitz, Yanish Purmah, et al.
Pageof 15